Several possible studies
Story checked
Enlicitide offers oral treatment option for patients avoiding cholesterol injections (opens in a new tab)
news-medical.net · 2026-10-05
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Enlicitide offers oral treatment option for patients avoiding cholesterol injections
news-medical.net · 2026-10-05
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Cited as backgroundpresented as the new finding
Enlicitide high cholesterol
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedEnlicitide is the first PCSK9 inhibitor available in pill form and offers a new treatment option for patients who prefer not to take injections.View evidenceHide evidence
As statedfirst PCSK9 inhibitor available in pill form
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 4Not checkedThe author says their phase three double-blind, randomized, placebo-controlled CORALreef Lipids clinical trial, published in The New England Journal of Medicine, contributed to FDA approval of enlicitide.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 4Not checkedAfter 24 weeks, enlicitide lowered LDL cholesterol by more than 57%, compared with a 3% decrease with placebo.View evidenceHide evidence
As statedmore than 57% vs 3% with placebo
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 4Not checkedThe article says enlicitide is potent at lowering LDL cholesterol, but it has not yet been proven to lower heart attacks and strokes and those studies are ongoing.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.
Expert Opinion on Pharmacotherapy · 2026 · PubMed, Europe PMC
Oral PCSK9 inhibitor enlicitide lowers LDL cholesterol levels in phase 2 trial
Nature Cardiovascular Research · 2026 · Crossref
Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis.
Journal of Cardiovascular Development and Disease · 2026 · PubMed, Europe PMC
Efficacy of yogurt drink with added plant stanol esters (Benecol®, Colanta) in reducing total and LDL cholesterol in subjects with moderate hypercholesterolemia: a randomized placebo-controlled crossover trial NCT01461798
Lipids in Health and Disease · 2014 · Crossref
New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9.
2026 · Europe PMC
And 10 more candidates considered.